- Home
- BSVN vs RGNX Comparison
BSVN vs RGNX Comparison
Compare BSVN & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSVN
- RGNX
- Stock Information
- Founded
- BSVN 2004
- RGNX 2008
- Country
- BSVN United States
- RGNX United States
- Employees
- BSVN 123
- RGNX N/A
- Industry
- BSVN Major Banks
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BSVN Finance
- RGNX Health Care
- Exchange
- BSVN Nasdaq
- RGNX Nasdaq
- Market Cap
- BSVN 414.8M
- RGNX 459.1M
- IPO Year
- BSVN 2018
- RGNX 2015
- Fundamental
- Price
- BSVN $44.42
- RGNX $10.95
- Analyst Decision
- BSVN Buy
- RGNX Strong Buy
- Analyst Count
- BSVN 3
- RGNX 11
- Target Price
- BSVN $37.00
- RGNX $37.80
- AVG Volume (30 Days)
- BSVN 36.7K
- RGNX 507.4K
- Earning Date
- BSVN 10-11-2024
- RGNX 11-06-2024
- Dividend Yield
- BSVN 2.14%
- RGNX N/A
- EPS Growth
- BSVN N/A
- RGNX N/A
- EPS
- BSVN 3.80
- RGNX N/A
- Revenue
- BSVN $85,876,000.00
- RGNX $84,327,000.00
- Revenue This Year
- BSVN N/A
- RGNX $7.85
- Revenue Next Year
- BSVN N/A
- RGNX $217.02
- P/E Ratio
- BSVN $12.47
- RGNX N/A
- Revenue Growth
- BSVN 10.72
- RGNX N/A
- 52 Week Low
- BSVN $21.89
- RGNX $8.54
- 52 Week High
- BSVN $47.56
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- BSVN 60.68
- RGNX 58.40
- Support Level
- BSVN $40.63
- RGNX $8.54
- Resistance Level
- BSVN $47.56
- RGNX $9.87
- Average True Range (ATR)
- BSVN 1.57
- RGNX 0.52
- MACD
- BSVN 0.21
- RGNX 0.12
- Stochastic Oscillator
- BSVN 63.35
- RGNX 75.14
About BSVN Bank7 Corp. Common stock
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a wide variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. it offers commercial real estate lending, hospitality lending, energy lending, and commercial and industrial lending, and also provides consumer lending services to individuals.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.